Anebulo Pharmaceuticals Shares Outstanding History (ANEB)
Anebulo Pharmaceuticals reported 41.1M shares outstanding at the end of fiscal 2025.
View full Anebulo Pharmaceuticals company overviewAnebulo Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | 41.1M | 15.2M | +58.43% |
| 2024 | 2024-06-30 | 25.9M | 300,000 | +1.17% |
| 2023 | 2023-06-30 | 25.6M | 2.3M | +9.80% |
| 2022 | 2022-06-30 | 23.3M | 0 | 0.00% |
| 2021 | 2021-06-30 | 23.3M | 11.3M | +94.54% |
| 2020 | 2020-06-30 | 12.0M | — | — |
Anebulo Pharmaceuticals quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2025-12-31 | 41.1M | 0 | 0.00% |
| Q1 2026 | 2025-09-30 | 41.1M | 15.2M | +58.43% |
| Q4 2025 | 2025-06-30 | 41.1M | 15.2M | +58.43% |
| Q3 2025 | 2025-03-31 | 41.1M | 15.2M | +58.43% |
| Q2 2025 | 2024-12-31 | 41.1M | 15.2M | +58.43% |
| Q1 2025 | 2024-09-30 | 25.9M | 300,000 | +1.17% |
| Q4 2024 | 2024-06-30 | 25.9M | 300,000 | +1.17% |
| Q3 2024 | 2024-03-31 | 25.9M | 300,000 | +1.17% |
| Q2 2024 | 2023-12-31 | 25.9M | 300,000 | +1.17% |
| Q1 2024 | 2023-09-30 | 25.6M | 0 | 0.00% |
| Q4 2023 | 2023-06-30 | 25.6M | 2.3M | +9.80% |
| Q3 2023 | 2023-03-31 | 25.6M | 2.3M | +9.80% |
| Q2 2023 | 2022-12-31 | 25.6M | 2.3M | +9.80% |
| Q1 2023 | 2022-09-30 | 25.6M | 2.3M | +9.80% |
| Q4 2022 | 2022-06-30 | 23.3M | 0 | 0.00% |
| Q3 2022 | 2022-03-31 | 23.3M | 10.4M | +79.82% |
| Q2 2022 | 2021-12-31 | 23.3M | 11.3M | +94.54% |
| Q1 2022 | 2021-09-30 | 23.3M | — | — |
| Q4 2021 | 2021-06-30 | 23.3M | — | — |
| Q3 2021 | 2021-03-31 | 13.0M | — | — |
| Q4 2020 | 2020-06-30 | 12.0M | — | — |
Anebulo Pharmaceuticals shares outstanding trends
Over the last five reported fiscal years, Anebulo Pharmaceuticals's shares outstanding moved from 12.0M to 41.1M, a change of 29.1M. The latest reported quarter, Q2 2026, shows 41.1M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anebulo Pharmaceuticals filings at SEC.gov ↗